Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model

被引:18
作者
Zelenitsky, SA [1 ]
Booker, B
Laing, N
Karlowsky, JA
Hoban, DJ
Zhanel, GG
机构
[1] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada
[2] Univ Manitoba, Fac Med, Winnipeg, MB R3T 2N2, Canada
[3] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB, Canada
关键词
D O I
10.1128/AAC.43.3.592
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacodynamics of an investigational glycopeptide, LY333328 (LY), alone and in combination with gentamicin, against one vancomycin-susceptible and two vancomycin-resistant Enterococcus faecium strains were studied with a multiple-dose, in vitro pharmacodynamic model (PDM), Dose-range data for the PDM studies mere obtained from static time-kill curve studies, In PDM experiments conducted over 48 h, peak LY concentrations of 0.1X and 1x the MIC every 24 h and peak gentamicin concentrations of 18 mu g/ml every 24 h (Gq24h) and 6 mu g/ml every 8 h (Gq8h) were studied atone and in the four possible LY-gentamicin combinations, Compared to either antibiotic alone, LY-gentamicin combination regimens produced significantly higher apparent killing rates (KRs) calculated during the initial 2 h postdosing, The mean KRs for LY or gentamicin alone versus those fur the LY-gentamicin combination regimens were 0.35 +/- 0.55 log(10) CFU/ml/h (95% confidence interval [CI95%], 0 to 0.70) and 1.46 +/- 0.71 log(10) CFU/ml/h (CI95%, 1.01 to 1.91), respectively (P < 0.0001). Bacterial killing at 48 h (BK48), which was calculated by subtracting the bacterial counts at 48 h from the initial inoculum, with a negative value indicating net growth, was also significantly greater. The mean BK(48)s were -0.69 +/- 0.44 log(10) CFU/ml (CI95%, -0.41 to -0.97) and 3.72 +/- 2.28 log(10) CFU/ml (CI95%, 2.28 to 5.17) for LY or gentamicin alone versus LY-gentamicin combination regimens, respectively (P < 0.0001). None of the 12 regimens with LY or gentamicin alone but 75% (9 of 12) of the LY-gentamicin combination regimens were bactericidal. Eighty-three percent: (10 of 12) of the LY-gentamicin combination regimens also demonstrated synergy. No significant differences between the pharmacodynamics of LY-gentamicin combination regimens containing Gq24h versus those containing Gq8h were detected.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 21 条
[2]  
Blaser J, 1990, Scand J Infect Dis Suppl, V74, P71
[3]  
CHIEN J, 1998, 38 INT C ANT AG CHEM, P18
[4]  
CURBELO DE, 1997, 37 INT C ANT AG CHEM, P289
[5]   VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BACTEREMIA - RISK-FACTORS FOR INFECTION [J].
EDMOND, MB ;
OBER, JF ;
WEINBAUM, DL ;
PFALLER, MA ;
HWANG, T ;
SANFORD, MD ;
WENZEL, RP .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1126-1133
[6]   ASSESSMENT OF EFFECTS OF PROTEIN-BINDING ON DAPTOMYCIN AND VANCOMYCIN KILLING OF STAPHYLOCOCCUS-AUREUS BY USING AN INVITRO PHARMACODYNAMIC MODEL [J].
GARRISON, MW ;
VANCEBRYAN, K ;
LARSON, TA ;
TOSCANO, JP ;
ROTSCHAFER, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1925-1931
[7]  
GAYNES R, 1996, INFECT CONT HOSP EP, V17, P18
[8]   Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period [J].
Iwen, PC ;
Kelly, DM ;
Linder, J ;
Hinrichs, SH ;
Dominguez, EA ;
Rupp, ME ;
Patil, KD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :494-495
[9]   In vitro activity and spectrum of LY333328, a novel glycopeptide derivative [J].
Jones, RN ;
Barret, MS ;
Erwin, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :488-493
[10]   Management of infections due to resistant enterococci: a review of therapeutic options [J].
Landman, D ;
Quale, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) :161-170